Literature DB >> 15465605

Neutrophils as a specific target for melatonin and kynuramines: effects on cytokine release.

S O Silva1, M R Rodrigues, V F Ximenes, A E B Bueno-da-Silva, G P Amarante-Mendes, A Campa.   

Abstract

A growing body of evidence suggests that the pineal hormone, melatonin, has immunomodulatory properties, although very little is known about its effect on leukocytes. Therefore, we aimed to investigate the effect of melatonin and its oxidation product N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) on cytokine production by neutrophils and peripheral blood mononuclear cells (PBMCs). AFMK (0.001-1 mM) inhibits the lipopolysaccharide (LPS)-mediated production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-8 (IL-8) more efficiently in neutrophils than PBMCs. Moreover, the inhibitory activity of AFMK is stronger than that of melatonin. Interestingly, monocytes efficiently oxidize melatonin to AFMK. We conclude that neutrophils are one of the main targets for melatonin and that at least part of the effects described for melatonin on immune cells may be due to its oxidation product, AFMK. We also consider that the oxidation of melatonin may be an important event in the cross-talking between neutrophils and monocytes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465605     DOI: 10.1016/j.jneuroim.2004.07.015

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  19 in total

Review 1.  A review of the multiple actions of melatonin on the immune system.

Authors:  Antonio Carrillo-Vico; Juan M Guerrero; Patricia J Lardone; Russel J Reiter
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

2.  Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes.

Authors:  E Hatanaka; P T Monteagudo; M S M Marrocos; A Campa
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

3.  Effect of melatonin on proliferation of neonatal cord blood mononuclear cells.

Authors:  Wei Zhou; Ping Wang; Li Tao
Journal:  World J Pediatr       Date:  2009-11-13       Impact factor: 2.764

4.  Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin.

Authors:  Caroline M Forrest; Gillian M Mackay; Nicholas Stoy; Trevor W Stone; L Gail Darlington
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

Review 5.  Neuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemia.

Authors:  Daniel Alonso-Alconada; Antonia Alvarez; Olatz Arteaga; Agustín Martínez-Ibargüen; Enrique Hilario
Journal:  Int J Mol Sci       Date:  2013-04-29       Impact factor: 5.923

6.  Melatonin metabolism in the central nervous system.

Authors:  Rüdiger Hardeland
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

7.  Seasonal changes in activities of human neutrophils in vitro.

Authors:  Magdalena Klink; Katarzyna Bednarska; Edyta Blus; Michal Kielbik; Zofia Sulowska
Journal:  Inflamm Res       Date:  2011-09-29       Impact factor: 4.575

Review 8.  Melatonin: buffering the immune system.

Authors:  Antonio Carrillo-Vico; Patricia J Lardone; Nuria Alvarez-Sánchez; Ana Rodríguez-Rodríguez; Juan M Guerrero
Journal:  Int J Mol Sci       Date:  2013-04-22       Impact factor: 5.923

Review 9.  Immune-pineal axis: nuclear factor κB (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells.

Authors:  Regina P Markus; Erika Cecon; Marco Antonio Pires-Lapa
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

Review 10.  Oxidative stress and immunosenescence: therapeutic effects of melatonin.

Authors:  Javier Espino; José A Pariente; Ana B Rodríguez
Journal:  Oxid Med Cell Longev       Date:  2012-12-31       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.